Japan’s Takeda Warns Against Rare Disease Drug After 20 Deaths

By VirentaNews Staff — May 16, 2026

Japanese pharmaceutical giant Takeda has issued a formal recommendation halting the prescription of its drug Nuplazid (generic name: ponesimod) to new patients with rare autoimmune diseases, following the deaths of 20 individuals who received the treatment. While the company emphasized that no definitive causal link has been established between the drug and the fatalities, the advisory marks a significant escalation in scrutiny over post-market safety protocols for therapies targeting ultra-rare conditions. The decision reflects growing pressure on pharmaceutical firms to balance aggressive innovation with rigorous, real-world risk monitoring—especially in patient populations with complex, overlapping comorbidities.

Death Toll and Clinical Data Under Review

According to data released by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), all 20 deaths occurred in adult patients diagnosed with primary biliary cholangitis (PBC) or other rare autoimmune disorders who had been prescribed ponesimod over the past 18 months. Of the cases, 14 involved patients over the age of 65, and 17 had pre-existing cardiovascular conditions, raising questions about drug interactions and patient selection. Ponesimod, a sphingosine-1-phosphate receptor modulator, was conditionally approved in Japan in 2021 for use in autoimmune diseases after early trials showed promise in reducing liver inflammation. However, post-marketing surveillance revealed a higher-than-expected incidence of severe cardiac events, including bradycardia and AV block, particularly during initial dosing. The PMDA is now conducting a comprehensive review of the clinical datasets, with preliminary findings expected within 90 days. The World Health Organization estimates that rare diseases collectively affect over 400 million people globally, making safety oversight in niche therapeutics a critical public health issue.

Takeda and Regulatory Bodies in Damage Control

Takeda Pharmaceutical, headquartered in Osaka, has positioned itself as a global leader in rare disease research, with over $2.3 billion invested in rare immunology therapies since 2020. The company’s decision to voluntarily restrict new prescriptions—while allowing ongoing patients to continue under physician supervision—suggests an attempt to maintain trust amid regulatory uncertainty. Japanese health authorities have not mandated a full recall, but the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) have both opened investigative files. In a recent statement, Takeda’s Chief Medical Officer, Dr. Yuki Tanaka, acknowledged the tragedy and reiterated the firm’s commitment to patient safety: ‘We are working closely with regulators to determine whether any specific risk factors contributed to these outcomes.’ Notably, ponesimod is not currently approved for PBC in the U.S. or EU, though it is under Phase III trials for multiple sclerosis. The incident has intensified debate over the adequacy of accelerated approval pathways, which allow drugs for rare conditions to reach market based on smaller, shorter trials.

Trade-Offs Between Innovation and Safety

The ponesimod controversy underscores a fundamental tension in rare disease drug development: the urgent need for treatments versus the imperative for long-term safety data. Patients with conditions like PBC often face limited therapeutic options, making even marginally effective drugs highly desirable. However, the small patient pools used in trials can obscure rare but serious side effects. In Takeda’s case, initial studies involving fewer than 500 patients failed to detect the cardiac risks that emerged in broader use. Regulatory bodies like the FDA have increasingly relied on post-market surveillance to catch such issues, but critics argue these systems are under-resourced and reactive. On the other hand, overly restrictive policies could delay life-saving innovations. The challenge lies in designing adaptive frameworks that mandate robust real-world monitoring without stifling development. As one Nature Medicine editorial noted, ‘The promise of precision medicine is undermined when safety systems fail to scale with innovation.’

Why the Timing Raises Red Flags

The timing of Takeda’s warning is significant—not only because of the accumulating death reports, but because it coincides with broader regulatory recalibrations in Japan’s pharmaceutical sector. In early 2023, the Ministry of Health, Labour and Welfare launched a task force to review conditional drug approvals, prompted by earlier controversies involving cancer therapeutics. Ponesimod’s approval pathway mirrored those under scrutiny, relying heavily on biomarker response rather than long-term clinical outcomes. Additionally, global attention on rare disease drugs has intensified, with the WHO declaring 2024–2034 the ‘Decade of Rare Diseases.’ This has increased pressure on manufacturers to demonstrate not just efficacy, but sustainable safety profiles. The fact that adverse events emerged within two years of market entry suggests that current monitoring intervals may be insufficient, particularly for drugs affecting immune and cardiovascular systems simultaneously.

Where We Go From Here

Looking ahead, three scenarios are plausible over the next 6 to 12 months. First, regulators may require Takeda to implement a risk evaluation and mitigation strategy (REMS), including mandatory cardiac monitoring during initiation, which could allow controlled resumption of prescriptions. Second, if causality is strengthened, a full withdrawal in Japan and clinical hold in other regions could follow, setting back rare autoimmune research by years. Third, the incident might catalyze international harmonization of post-market surveillance standards, with agencies like the FDA, EMA, and PMDA establishing shared databases for rare disease drug safety. Each path carries implications for patient access, corporate liability, and public trust in pharmaceutical innovation.

Bottom line — while Takeda’s proactive warning may prevent further harm, the ponesimod case exposes systemic vulnerabilities in how rare disease therapies are approved and monitored, demanding urgent reforms to protect the world’s most vulnerable patients.

Source: MedicalXpress